Back
BITR
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Biotron Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Growth
7 months capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
7
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Biotron Limited - Rights - Applications Close 01-Apr-2025
π Performance
Price History
0.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.00
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in BITR
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in BITR
N/A
BITR investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in BITR also invest in...
Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The firm has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The firm also has a portfolio of preclinical antiviral programs.
π Performance (5Yr p.a)
-19.33%
π Share price
$0.00 AUD
𧬠BIOTECHNOLOGY
Kogan.com Ltd. engages in the business of a portfolio of retail and services. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2016-07-07. The Companyβs businesses include Kogan Retail, Kogan Marketplace, Kogan Mobile, Kogan Internet, Kogan Insurance, Kogan Money, Kogan Energy, Kogan Travel, Dick Smith, Matt Blatt, Mighty Ape and Brosa. Its segments include Kogan.com and Mighty Ape. Kogan.com segment is an online retailer selling in-house and third-party brand household and consumer electronics products, as well as providing services for telecommunication, Internet, insurance, home finances, utilities, vehicles and travel. The Mighty Ape segment is an online specialist retailer of gaming and entertainment products. Its offering comprises products released under Kogan.comβs brands, such as Kogan, Ovela, Fortis, Certa and Komodo, and products sourced from imported and domestic third party brands such as Apple, Canon, Swann, and Samsung. The company trades through various channels, including the Kogan.com Website and Apps and the Dick Smith Website.
π Performance (5Yr p.a)
-16.66%
π Share price
$3.44 AUD
ποΈ CONSUMER
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8332.1m in AUM and 198 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
π Performance (5Yr p.a)
9.37%
π Share price
$147.69 AUD
π¦πΊ AUSTRALIA
πΈ FINANCIALS
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
17.44%
π Share price
$150.38 AUD
π GLOBAL
π€ TECHNOLOGY
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
8.78%
π Share price
$110.13 AUD
π¦πΊ AUSTRALIA
πΈ FINANCIALS
π§± MATERIALS
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
Want more shares? Try these...